WO2006063402A1 - Préparations thérapeutiques basées sur des extraits de plantes du genre piumeria (frangipani) - Google Patents

Préparations thérapeutiques basées sur des extraits de plantes du genre piumeria (frangipani) Download PDF

Info

Publication number
WO2006063402A1
WO2006063402A1 PCT/AU2005/001897 AU2005001897W WO2006063402A1 WO 2006063402 A1 WO2006063402 A1 WO 2006063402A1 AU 2005001897 W AU2005001897 W AU 2005001897W WO 2006063402 A1 WO2006063402 A1 WO 2006063402A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
plant
plumeria
genus
Prior art date
Application number
PCT/AU2005/001897
Other languages
English (en)
Inventor
Melvin Mackenzie Stewart
Original Assignee
Melvin Mackenzie Stewart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004907148A external-priority patent/AU2004907148A0/en
Application filed by Melvin Mackenzie Stewart filed Critical Melvin Mackenzie Stewart
Publication of WO2006063402A1 publication Critical patent/WO2006063402A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to therapeutic compositions and methods of treatment utilising extracts of plants from the genus Plumeria.
  • the invention relates to compositions and methods for treating skin cancers, fungal infections, viral infections, defects of the skin as well as other disorders.
  • Plumeria also known as Plumiera, common name Frangipani
  • Species of Plumeria include P. rubra, P. acutifolia, P. obtusa, P. obtusifolia, P. alba, P. bicolor, P. tricolour and P. jamesoni.
  • Plumeria Various uses for Plumeria have been described.
  • the specification of GB 2 104 383 describes anti- fouling compositions prepared from Plumeria, for use as algicides and barnicides in paints.
  • Hamburger et al J. Ethnopharmacol. 1991 JuI; 33(3):289-92
  • bioactive compounds prepared from P. rubra having molluscicidal, cytotoxic and anti-bacterial activities. Extracts of the flowers of Plumeria have also been used as fragrances in cosmetics.
  • extracts of Plumeria also have therapeutic properties and can be used in the prevention or treatment of skin cancers, fungal infections, viral infections, various skin defects and other afflictions.
  • compositions for preventing or treating skin cancer comprising an extract from a plant of the genus Plumeria.
  • a method for preventing or treating skin cancer in a subject comprising the step of administering to the subject a c ' omp ' bsiti ⁇ n comprising an extract from a plant of the genus Plumeria.
  • a third aspect of the present invention there is provided the use of an extract from a plant of the genus Plumeria in the preparation of a medicament for the prevention or treatment of skin cancer in a subject.
  • compositions for preventing or treating a fungal infection comprising an extract from a plant of the genus Plumeria.
  • a method for preventing or treating a fungal infection in a subject comprising the step of administering to the subject a composition comprising an extract from a plant of the genus Plumeria.
  • an extract from a plant of the genus Plumeria in the preparation of a medicament for the prevention or treatment of a fungal infection in a subject.
  • compositions for preventing or treating a viral infection comprising an extract from a plant of the genus Plumeria.
  • a method for preventing or treating a viral infection in a subject comprising the step of administering to the subject a composition comprising an extract from a plant of the genus Plumeria.
  • a ninth aspect of the present invention there is provided the use of an extract from a plant of the genus Plumeria in the preparation of a medicament for the prevention or treatment of a viral infection in a subject.
  • a composition for repairing or preventing a defect of the skin comprising an extract from a plant of the genus Plumeria.
  • a method of repairing or preventing a defect of the skin in a subject comprising the step of administering to the subject a composition comprising an extract from a plant of the genus Plumeria.
  • an extract from a plant of the genus Plumeria in the preparation of a medicament for repairing or preventing a defect of the skin in a subject.
  • compositions for preventing or treating haemorrhoids comprising an extract from a plant of the genus Plumeria.
  • a fourteenth aspect of the present invention there is provided a method of preventing or treating haemorrhoids in a subject, said method comprising the step of administering to the subject a composition comprising an extract from a plant of the genus Plumeria.
  • an extract from a plant of the genus Plumeria in the preparation of a medicament for preventing or treating haemorrhoids in a subject.
  • a sixteenth aspect of the present invention there is provided a method for preparing a composition comprising an extract from a plant of the genus Plumeria, the composition being as described in other aspects of the invention.
  • extracts of plants of the genus Plumeria have anti-cancer, antifungal and anti-viral activities as well as other therapeutic-properties;- Although the extract may be derived from any suitable species of the Plumeria genus (including P. rubra, P. acutifolia, P. obtusa, P. obtusifolia, P. alba, P. bicolor, P. tricolour and P. jamesoni), deciduous forms of Plumeria are preferred as they appear to have the highest activities.
  • the extract is derived from P. rubra.
  • the extract can be prepared from any suitable part or parts of the plant.
  • the extract can be prepared, for instance, from the branches, leaves, trunk, bark, milky sap (latex), flowers or roots of the plant.
  • the extract comprises milky sap collected from actively growing branches of the plant. Milky sap is exuded from the branches when bruised, cut or punctured. If necessary, the sap can be processed or stabilised in any suitable way.
  • the composition can be used to prevent or treat any suitable type of skin cancer.
  • the composition can, for instance, be used to prevent or treat squamous cell carcinoma, basal cell carcinoma, melanoma, Kaposi's sarcoma, cutaneous lymphoma, adnexal tumour and Merkel cell carcinoma.
  • the composition can also be used to prevent or treat precursors of skin cancer such as solar keratoses.
  • the composition can be used to prevent or treat any suitable type of fungal infection.
  • the composition is used to prevent or treat tinea (e.g. athlete's foot, jock itch, ringworm, deep nail bed infection) which is caused chiefly by species of Microsporum, Trichophyton, Candida and Epidermophyton.
  • the composition can be used to prevent or treat any suitable type of viral infection.
  • the composition is applied to sores, ulcers, lesions, blisters, cancers, inflammations, skin discolorations and other skin defects that are caused by a virus. Some of these are caused, for example, by herpes simplex virus 1 or 2 which primarily affect the mouth and genital areas. Human papillomavirus may cause carcinomas in genital areas.
  • the composition can be used to prevent or treat any suitable defect of the skin.
  • the skin defect may be, for example, an age spot, a benign- tumour, a -blister, a burn, chicken pox, a cold-sore, a- crack, cradle cap, dermatitis, diaper rash, eczema, a lesion, a mole, a papule, a pustule, a reddened area, rosacea, scaling, a stomatitis, an ulcer, a wound, or seborrhoeic keratosis.
  • compositions described above can be formulated as a pharmaceutical or a cosmeceutical.
  • Each composition can be administered to the subject in any suitable form in any suitable way.
  • the subject is a human or other mammal.
  • Each composition can be, for instance, administered topically in the form of a cream, foam, gel, milk, lotion, oil, ointment, paste, powder or solution.
  • the compound can be incorporated into a bandage or plaster.
  • each composition is applied topically as a cream at least once, but preferably twice, a day.
  • composition of the present invention can include one or more other active ingredients.
  • An active ingredient as defined herein, is a compound that provides therapeutic benefit to the subject.
  • the active ingredient can be, for instance, an antibiotic, antifungal, anti-inflammatory, anti-viral or wound healer.
  • Salicylic acid and paraffin are examples of such ingredients.
  • the composition further comprises the active ingredients benzoic acid and salicylic acid.
  • these ingredients have been used topically as an antifungal and keratolytic agent in the treatment of tinea pedis (commercially available as Whitfield's OintmentTM), the inventor has found synergy between the plant extract and one or more of the ingredients so as to more efficiently treat fungal infections.
  • composition of the present invention can further include one or more of the following types of ingredients: an adhesive, a base, a buffer, a carrier, a colourant, a diluent, a dispersing agent, an emollient, an emulsifier, an excipient, a fiexibiliser/plasticiser, fragrance, a gelling agent, a humectant, an insecticidal agent, a lubricant, a preservative, a skin conditioning agent, a skin protectant, a solubiliser, a stabilising agent, a sunscreen agent, a surfactant, a suspending agent, a textural modifier, a thickening agent, a viscosity increasing agent, and a waterproofing agent.
  • an adhesive a base, a buffer, a carrier, a colourant, a diluent, a dispersing agent, an emollient, an emulsifier, an excipient, a fiexibiliser/plasticiser,
  • Suitable organic, -oily- or aqueous bases, carriers, - diluents and -excipients are inert and physiologically acceptable and include, for example: bacteriostatic saline (saline containing benzyl alcohol), cetomacrogol, cetyl alcohol, glycerine, lanolin, petrolatum based creams, gels, saline, short chain alcohols and glycols (e.g. ethyl alcohol and propylene glycol), and water.
  • An emollient can help skin maintain a soft, smooth and pliable appearance.
  • the emollient can be, for example: acetyl arginine, acetylated lanolin, algae extract, almond oil, apricot kernel oil PEG-6 esters, avocado oil PEG-I l esters, bis-PEG-4 dimethicone, butoxyethyl stearate, C 18 -C 36 acid glycol ester, C 2 -Ci 3 alkyl lactate, caprylyl glycol, cetyl alcohol, cetyl esters, cetyl laurate, coconut oil PEG-IO esters, crodamol GTCC, di- Cj 2 -C 13 alkyl tartrate, diethyl sebacate, dihydrocholesteryl butyrate, dimethiconol, dimyristyl tartrate, disteareth-5 lauroyl glutamate, ethyl avocadate, ethylhexy
  • Either water in oil or oil in water emulsions can be used.
  • suitable surfactants and emulsifying agents include: non-ionic ethoxylated and non-ethoxylated surfactants, abietic acid, almond oil PEG, beeswax, butylglucoside caprate, C 18 -C 36 acid glycol ester, Cg-C 1S alkyl phosphate, caprylic/capric triglyceride PEG-4 esters, cetomacrogol, ceteareth-7, cetereth-20, cetyl phosphate, cetyl stearyl alcohol, corn oil PEG esters, DEA-cetyl phosphate, dextrin laurate, dilaureth-7 citrate, dimyristyl phosphate, glycereth-17 cocoate, glyceryl erucate, glycerol, glyceryl laurate, G.M.S.
  • PEG esters isosteareth-11 carboxylic acid, lecithin, lysolecithin, nonoxynol-9, octyldodeceth-20, palm glyceride, PEG diisostearate, PEG stearamine, poloxamines, polyglyceryls, potassium linoleate, PPGs, raffinose myristate, sodium caproyl lactylate, sodium caprylate, sodium cocoate, sodium isostearate, sodium tocopheryl phosphate, steareths, TEA-C 12 -C 13 pareth-3 sulfate, Ui-Ci 2 -C 15 pareth-6 phosphate, and trideceths.
  • a humectant can help maintain moisture levels in skin.
  • the humectant can be for example: acetyl arginine, algae extract, aloe barbadensis leaf extract, betaine, 2, 3-butanediol, chitosan lauroyl glycinate, diglycereth-7 malate, diglycerin, diglycol guanidine succinate, erythritol, fructose, glucose, glycerine, honey, hydrolyzed wheat protein/PEG-20 acetate copolymer, hydroxypropyltrimonium hyaluronate, inositol, lactitol, maltitol, maltose, mannitol, mannose, methoxy PEG, myristamidobutyl guanidine acetate, polyglyceryl sorbitol, potassium PCA, propylene glycol, sodium PCA, sorbitol, sucrose, and urea
  • Each composition can include one or more types of preservative.
  • a suitable preservative for example, can be: benzalkonium chloride, benzoic acid, benzothonium chloride, benzyl alcohol, 2- bromo-2-nitropropane-l,3-diol, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butyl paraben, chlorophene, chlorphenesin, diazolidinyl urea, DMDM hydantoin, ethyl paraben, formaldehyde-releasing preservative, hydroquinone, iodopropynyl butylcarbamate, imidazolidinyl urea, methyldibromo glutaronitrile, methylhydroquinone, methylisothiazolinone, methyl paraben, nitrosamines, o-cymen-5-ol, phenoxyethanol, propyl parab
  • a skin conditioning agent improves dry or damaged skin.
  • agents include: acetyl cysteine, N-acetyl dihydrosphingosine, acrylates/behenyl acrylate/dimethicone acrylate copolymer, adenosine, adenosine cyclic phosphate, adensosine phosphate, adenosine triphosphate, alanine, albumen, algae extract, allantoin and deriviatives, aloe barbadensis extracts, aluminum PCA, amyloglucosidase, arbutin, arginine, azulene, bromelain, buttermilk powder, butylene glycol, caffeine, calcium gluconate, capsaicin, carbocysteine, carnosine, beta-carotene, casein, catalase, cephalins, ceramides, chamomilla recutita (matricaria) flower extract,
  • a skin protectant protects injured or exposed skin or mucous membrane surfaces from harmful or irritating chemicals.
  • a skin protectant for example, includes: algae extract, allantoin, aluminium hydroxide, aluminium sulfate, betaine, camellia sinensis leaf extract, cerebrosides, dimethicone, glucuronolactone, glycerin, kaolin, lanolin, malt extract, mineral oil, petrolatum, potassium gluconate, and talc.
  • the sunscreen agent can absorb, reflect or scatter UV radiation in the wavelength range of about 290 to 400 nanometers.
  • Such agents include: benzophenone-3 (oxybenzone), benzophenone-4
  • thickening or viscosity increasing agents include: acrylamides copolymer, agarose, amylopectin, bentonite, calcium alginate, calcium carboxymethyl cellulose, carbomer, carboxymethyl chitin, castor oil derivatives, cellulose gum, cellulosic preparation, cetyl alcohol, cetostearyl alcohol, coconut oil, dextrin, gelatin, hydrogenated tallow, hydroxyethylcellulose, hydroxypropylcellulose, hydroxpropyl starch, inorganic thixotrope, magnesium alginate, methylcellulose, microcrystalline cellulose, modified clays, paraffin, pectin, various PEG's, polyacrylic acid, polymethacrylic acid, polyvinyl alcohol, quaternium ammonium compound of bentonite or zinc stearate, shea butter, various PPG's, "sodium acrylates copolymer, sodium- carrageenan, silicon dioxide, xanthum gum, and yeast beta-glucan
  • each composition comprises: about 25% volume/volume sap from a plant of the genus P ⁇ umeria; and a base having about 15% volume/volume Whitfield's OintmentTM pre-mixed with about 60% volume/volume either Vitamin E Cream or Sorbelene Cream.
  • the base has a low alcohol content.
  • Whitfield's OintmentTM can comprise 3 g/50 g benzoic acid and 1.5 g/50 g salicylic acid in a lanolin, petroleum jelly or other type of organic base. Whitfield's OintmentTM can be as manufactured by Gilseal Coy, Queensland, Australia or Biotech Pharmaceuticals, Queensland,
  • Vitamin E Cream can comprise tocopheryl acetate in an oily base. Vitamin E Cream can be as manufactured by Liberty Cosmetics, New South Wales, Australia.
  • Sorbelene Cream (being an emulsion) can comprise water, glycerine, cetamacrogol, liquid paraffin, cetyl stearyl alcohol, methyl paraben, propyl paraben and imidazolindinyl urea as manufactured by Amcal Chemists Ltd, Victoria, Australia, Jean Charles Professional Products, New South Wales, Australia or Lustra Labs., Victoria, Australia.
  • This example describes the preparation of a therapeutic cream comprising an extract of Plumeria rubra.
  • a green -tipped branch of a Plumeria rubra plant was punctured with a knife and 12-20 drops of the milky sap (latex) of the plant were collected in a container.
  • the sap was mixed with a base comprising about 15% volume/volume Whitfield's OintmentTM (manufactured by Gilseal Coy, Queensland, Australia or Biotech Pharmaceuticals, Queensland, Australia) pre-mixed with about 60% volume/volume either Vitamin E Cream (manufactured by Liberty Cosmetics, New South Wales, Australia) or Sorbelene Cream (manufactured by Amcal Chemists Ltd, Victoria, Australia, Jean Charles Professional Products, New South Wales, Australia or Lustra Labs., Victoria, Australia).
  • the volume of sap in the cream composition was about 25%.
  • Whitfield's OintmentTM typically comprises 3 g/50 g benzoic acid and 1.5 g/50 g salicylic acid in a lanolin or petroleum jelly (organic) base.
  • Vitamin E Cream typically comprises tocopheryl acetate in an oily base.
  • Sorbelene Cream (being an emulsion) typically comprises water, glycerine, cetamacrogol, liquid paraffin, cetyl stearyl alcohol, methyl paraben, propyl paraben and imidazolindinyl urea.
  • the latex Since the latex separates/coagulates on exposure to air, the latex should be mixed with the base as soon as possible.
  • One way of checking to see that there is sufficient latex in the composition is to place some of the composition between the forefinger and thumb. If there is insufficient latex in the composition, many fine latex-derived strands will not be evident when moving the thumb and forefinger away from one another.
  • Example 1 The cream as described in Example 1 has been proven effective for the treatment of various cancers and pre-cancers, including: tumours of advanced breast cancer, viral penile carcinoma, squamous cell carcinoma (nose, hand, chest, vagina, leg), melanoma (ear, back, chest, neck, face), solar keratoses (hand, nose) and basal cell carcinoma (ear, face, arm, leg).
  • tumours of advanced breast cancer including: tumours of advanced breast cancer, viral penile carcinoma, squamous cell carcinoma (nose, hand, chest, vagina, leg), melanoma (ear, back, chest, neck, face), solar keratoses (hand, nose) and basal cell carcinoma (ear, face, arm, leg).
  • the cream was applied to the skin cancer or cancer precursor once or twice a day. No adverse reactions were reported, the cream did not irritate the skin nor did it inflame the skin. On average, melanomas disappeared and were replaced by new healthy skin usually within three weeks. Solar keratoses, on average, disappeared and were replaced by new healthy skin usually within 10 days. On average, squamous cell carcinomas disappeared and were replaced by new healthy skin usually within two weeks.
  • Cancers have also been treated on the lower eyelids, face and back of the head, with the cancers usually disappearing within a matter of 2-3 weeks.
  • the cream also appeared to elicit an immune response (to have "memory") whereby newly appearing squamous cell carcinomas would disappear within a matter of days without requiring fresh application of the cream.
  • compositions for treating skin cancer include that the composition specifically targets cancerous cells as opposed to surrounding healthy cells (unlike radiotherapy and chemotherapy), invasive surgical procedures (cancer removal using liquid nitrogen or surgical incision) can be avoided, and cancers on generally inoperable parts of the body can be treated (e.g. cancers on the lower eyelids).
  • a punch specimen 3 mm in diameter and 2 mm in depth was taken of a lesion on a hand, and the specimen was embedded. Microscopic sections showed hyperkeratotic moderate to severely dysplastic solar keratosis in the punch specimen. Upon application of the cream twice daily for eight days, the lesion was confirmed by a doctor as having resolved.
  • a biopsy was taken of a lesion on a hand (a skin ellipse 7 x 2 x 2 mm with a slightly elevated cream area 2 mm).
  • the biopsy showed the lesion to be an early well differentiated squamous cell carcinoma in skin with solar degeneration.
  • the cream twice daily for less than three weeks the lesion was confirmed by a doctor as having resolved.
  • Example 1 The cream as described in Example 1 has been proven effective for the treatment of fungal conditions, including athlete's foot and ringworm.
  • Example 1 The cream as described in Example 1 has been proven effective for the treatment of sores, ulcers, lesions, blisters, cancers, inflammations and skin discolorations that are caused by a virus.
  • the cream was applied twice a day.
  • the cream was used to effectively treat conditions caused by herpes simplex virus in the mouth and genital areas. The conditions cleared up within 2-3 weeks.
  • the cream was also used to effectively treat carcinomas in genital areas caused by human papilloma virus. The carcinomas disappeared within 3 weeks.
  • Example 5 Treatment of Skin Defects and Other Conditions
  • the cream as described in Example 1 has been proven effective for the treatment of various skin defects and haemorrhoids.
  • the cream has been used to treat eczema, dermatitis, brown age spots, moles, burns and seborrhoeic keratoses.
  • the cream was applied once or twice a day. Eczema, dermatitis and brown age spots cleared up or improved usually within about seven days. Haemorrhoids were effectively treated within 2-3 weeks. Seborrhoeic keratoses (maxillary area) were effectively treated within about three weeks. In one instance, brown age spots (on the backs of hands) faded after about four weeks. A growing dark brown mole (on the side of a nose) dropped off in less than three weeks, leaving smooth healthy skin with no scar tissue at all.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention a pour objet une préparation thérapeutique pour application locale qui comprend un extrait d'une plante du genre Plumeria. Ladite préparation peut être employée dans la prévention et le traitement de cancers de la peau, d'infections fongiques, d'infections virales et d'hémorroïdes. Ladite préparation peut également être employée pour réparer et prévenir les défauts de la peau.
PCT/AU2005/001897 2004-12-16 2005-12-15 Préparations thérapeutiques basées sur des extraits de plantes du genre piumeria (frangipani) WO2006063402A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004907148 2004-12-16
AU2004907148A AU2004907148A0 (en) 2004-12-16 Plant-Based Therapeutic Compositions

Publications (1)

Publication Number Publication Date
WO2006063402A1 true WO2006063402A1 (fr) 2006-06-22

Family

ID=36587460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2005/001897 WO2006063402A1 (fr) 2004-12-16 2005-12-15 Préparations thérapeutiques basées sur des extraits de plantes du genre piumeria (frangipani)

Country Status (1)

Country Link
WO (1) WO2006063402A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293227B2 (en) 2004-01-22 2012-10-23 University Of Miami Topical co-enzyme Q10 formulations and methods of use
US8815308B2 (en) 2010-12-30 2014-08-26 Mary Kay, Inc. Multi-purpose cosmetic compositions
WO2014163960A1 (fr) * 2013-03-11 2014-10-09 Avon Products, Inc Extraits de plumeria acuminata et procédés d'utilisation
US8877259B2 (en) 2012-02-09 2014-11-04 Mary Kay Inc. Cosmetic formulation
US9896731B2 (en) 2009-05-11 2018-02-20 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US9901542B2 (en) 2013-09-04 2018-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
US10376477B2 (en) 2011-04-04 2019-08-13 Berg Llc Method of treating or preventing tumors of the central nervous system
US10668028B2 (en) 2008-04-11 2020-06-02 Berg Llc Methods and use of inducing apoptosis in cancer cells
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
US11707427B2 (en) 2020-04-29 2023-07-25 Mary Kay Inc. Cosmetic compositions and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9705331A (pt) * 1997-10-29 2000-04-18 Elba Diniz Bueno Pomada anti-inflamatória e cicatrizante de uso tópico e processo para sua obtenção
JP2001261544A (ja) * 2000-03-21 2001-09-26 Kose Corp 皮膚外用剤
JP2002097151A (ja) * 2000-07-21 2002-04-02 Maruzen Pharmaceut Co Ltd 皮膚外用剤
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
EP1527783A1 (fr) * 2003-10-31 2005-05-04 Health Research, Inc. Composés iridoide-saccharide et méthode pour leur utilisation
WO2005087246A1 (fr) * 2004-03-12 2005-09-22 Kuniaki Nerome Agent antitumoral

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9705331A (pt) * 1997-10-29 2000-04-18 Elba Diniz Bueno Pomada anti-inflamatória e cicatrizante de uso tópico e processo para sua obtenção
JP2001261544A (ja) * 2000-03-21 2001-09-26 Kose Corp 皮膚外用剤
JP2002097151A (ja) * 2000-07-21 2002-04-02 Maruzen Pharmaceut Co Ltd 皮膚外用剤
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
EP1527783A1 (fr) * 2003-10-31 2005-05-04 Health Research, Inc. Composés iridoide-saccharide et méthode pour leur utilisation
WO2005087246A1 (fr) * 2004-03-12 2005-09-22 Kuniaki Nerome Agent antitumoral

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"The Herpes News", THE HERPES NEWS ARCHIVE, March 1999 (1999-03-01), Retrieved from the Internet <URL:http://www.raccon.com/theherpesnews/99MAR.htm> *
"Workers", no. 66, 11 August 2000 (2000-08-11), Retrieved from the Internet <URL:http://workers.labor.net.au/66/b_tradeunion_nurse.html> *
DATABASE WPI Week 200032, Derwent World Patents Index; Class B04, AN 2000-365980 *
DATABASE WPI Week 200204, Derwent World Patents Index; Class B04, AN 2002-029792 *
DATABASE WPI Week 200270, Derwent World Patents Index; Class B04, AN 2002-646987 *
DATABASE WPI Week 200566, Derwent World Patents Index; Class B04, AN 2005-649462 *
GEVARA A.P. ET AL.: "Antimutagens from Plumeria acuminata Ait", MUTATION RESEARCH, vol. 361, no. 2-3, 1996, pages 67 - 72 *
HAMBURGER M.O. ET AL.: "Traditional medicinal plants of Thailand. XVII. Biologically active constituents of Plumeria rubra", J. ETHNOPHARMACOLOGY, vol. 33, no. 3, 1991, pages 289 - 292 *
KARDONO L.B. ET AL.: "Cytotoxic constituents of the bark of Plumeria rubra collected in Indonesia", J. NATURAL PRODUCTS, vol. 53, no. 6, 1990, pages 1447 - 1455 *
LEVEN M. ET AL.: "Screening of higher plants for biological activities. I. Antimicrobial Activity", PLANTA MEDICA, vol. 36, 1979, pages 311 - 321 *
TAN G.T. ET AL.: "Evaluation of natural products as inhibitory of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase", J. NATURAL PRODUCTS, vol. 54, no. 1, 1991, pages 25 - 32 *
VAN DEN BERGHE D.A. ET AL.: "Screening of Higher Plants for Biological Activities. II. Antiviral activity", LLOYDIA, vol. 41, no. 5, 1978, pages 463 - 471 *
WAGNER H. AND WOLFF P.: "New Natural Products with Pharmacological, Biological or Therapeutical Activity", 1977, SPRINGER VERLANG,, BERLIN, article "Plant Mono-, Di-, and Sesquiterpenoids with Pharmacological or Therapeutical Activity", pages: 137 - 176 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562976B2 (en) 2004-01-22 2013-10-22 University Of Miami Co-enzyme Q10 formulations and methods of use
US8586030B2 (en) 2004-01-22 2013-11-19 University Of Miami Co-enzyme Q10 formulations and methods of use
US8771680B2 (en) 2004-01-22 2014-07-08 University Of Miami Topical co-enzyme Q10 formulations and methods of use
US8293227B2 (en) 2004-01-22 2012-10-23 University Of Miami Topical co-enzyme Q10 formulations and methods of use
US10668028B2 (en) 2008-04-11 2020-06-02 Berg Llc Methods and use of inducing apoptosis in cancer cells
US9896731B2 (en) 2009-05-11 2018-02-20 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US10351915B2 (en) 2009-05-11 2019-07-16 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10)
US11028446B2 (en) 2009-05-11 2021-06-08 Berg Llc Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US9320702B2 (en) 2010-12-30 2016-04-26 Mary Kay Inc. Multi-Purpose cosmetic compositions
US9358203B2 (en) 2010-12-30 2016-06-07 Mary Kay Inc. Multi-purpose cosmetic compositions
US10842733B2 (en) 2010-12-30 2020-11-24 Mary Kay Inc. Multi-purpose cosmetic compositions
US10188595B2 (en) 2010-12-30 2019-01-29 Mary Kay Inc. Multi-purpose cosmetic compositions
US11857667B2 (en) 2010-12-30 2024-01-02 Mary Kay Inc. Multi-purpose cosmetic compositions
US8815308B2 (en) 2010-12-30 2014-08-26 Mary Kay, Inc. Multi-purpose cosmetic compositions
US11452699B2 (en) 2011-04-04 2022-09-27 Berg Llc Method of treating or preventing tumors of the central nervous system
US10376477B2 (en) 2011-04-04 2019-08-13 Berg Llc Method of treating or preventing tumors of the central nervous system
US8877259B2 (en) 2012-02-09 2014-11-04 Mary Kay Inc. Cosmetic formulation
US9283171B2 (en) 2012-02-09 2016-03-15 Mary Kay Inc. Cosmetic formulation
WO2014163960A1 (fr) * 2013-03-11 2014-10-09 Avon Products, Inc Extraits de plumeria acuminata et procédés d'utilisation
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
US9901542B2 (en) 2013-09-04 2018-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
US11298313B2 (en) 2013-09-04 2022-04-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
US11707427B2 (en) 2020-04-29 2023-07-25 Mary Kay Inc. Cosmetic compositions and methods

Similar Documents

Publication Publication Date Title
US7179789B2 (en) Compositions and methods for treatment of rosacea
WO2006063402A1 (fr) Préparations thérapeutiques basées sur des extraits de plantes du genre piumeria (frangipani)
US7186687B2 (en) Compositions and methods for treatment of Psoriasis
US20190167765A1 (en) Human serum albumin-based topical ointment for treatment of acne, psoriasis, egfr-induced toxicity, premature skin aging and other skin conditions
US20040180102A1 (en) Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto
US20030134780A1 (en) Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof
US20030134781A1 (en) Methods for the treatment of hyperpigmentation of skin
WO2006004787A1 (fr) Procédés et composition pour la prévention et le traitement de l’hyperpigmentation de la peau
FR2978664A1 (fr) Composition antiseptique
KR20190013101A (ko) 흉터의 예방 또는 치료를 위한 조성물
US20060052287A1 (en) Polyethylene glycol - peptide copper complexes and compositions and methods related thereto
KR102113317B1 (ko) 흉터의 예방 또는 치료를 위한 조성물
US11865138B2 (en) Methods and compositions for therapeutic skin treatments in dermatological procedures affecting skin&#39;s barrier
KR20200056366A (ko) 흉터의 예방 또는 치료를 위한 조성물
US20230321006A1 (en) Putrescine topical barrier formulation
AU2002332062A1 (en) Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815668

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 5815668

Country of ref document: EP